TheraPsil

Depression Relief: Possible Therapy Boost With DMT & SSRIs Small Pharma Clinical Results New findings on safety, tolerability and efficacy from a clinical study assessing the interaction of psychedelics and traditional pharma for the treatment of major depressive disorder (MDD) are out....

Canadian not-for-profit organization TheraPsil has received board approval to launch its training program on MDMA-assisted psychotherapy for trauma survivors. TheraPsil has been advancing legal access to psychedelic-assisted psychotherapy since 2019. The new course, which joins the...

Health-Canada licensed psychedelics biotech Lucy Scientific Discovery (NASDAQ: LSDI) and not-for-profit psilocybin advocate organization TheraPsil have partnered toward advancing medical psilocybin access and research. Since 2019, TheraPsil has worked on lawful and compassionate access to...

Ontario-based Red Light Holland Corp. (OTCQB: TRUFF) has committed to becoming an aligned supporter and advocate with the non-profit TheraPsil. The two entities are engaged in advancing a charter challenge relating to the prohibition of psilocybin under the Controlled Drugs and Substances Act (CDSA...

TheraPsil, a Canadian coalition for psilocybin therapy legalization, together with the U.K. independent foundation Drug Science, has launched Project Solace. The goal is to gather data to better inform patients about the development of regulated psilocybin products. That way it can document...

Cybin Debuts On The NYSE Last week, Cybin (NYSE: CYBN) began listing its stock on the New York Stock Exchange. The company is the first in the sector to enter the NYSE, following a trend of five psychedelics companies to debut on the Nasdaq since the beginning of the year. “This validation by...

While many 2020 memories will be gladly left behind, that's not necessarily the case for psychedelics. There was unprecedented renaissance as psychedelic compounds, and their potential to treat mental health conditions, became one of the centerpieces of this year’s public...

Global Developments in Germany, Canada and Brazil Germany has approved a large phase 2b study on psilocybin for treatment-resistant depression. Dr. Gerhard Gründer, of the Central Institute of Mental Health Mannheim, will lead the study alongside the Department of Psychiatry and...

Canadian Government Allows Psilocybin Treatment to 4 Terminally-Ill Patients In a landmark decision, the Canadian Minister of Health Patty Hajdu allowed four terminally-ill cancer patients to legally use psilocybin as part of a palliative care treatment for end-of-life distress. This is the first...